연구동향 분석
박사

Function of MUDENG in Glioblastoma and A Possibility of Novel Therapeutic Target = Glioblastoma에서 MUDENG의 기능과 치료 타겟으로써 가능성

최준하 2020년

논문상세정보
인용/피인용
' Function of MUDENG in Glioblastoma and A Possibility of Novel Therapeutic Target = Glioblastoma에서 MUDENG의 기능과 치료 타겟으로써 가능성' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • Bik
  • Drug resistance
  • MuD
  • anti-apoptosis
  • gbm
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
90 0

0.0%

' Function of MUDENG in Glioblastoma and A Possibility of Novel Therapeutic Target = Glioblastoma에서 MUDENG의 기능과 치료 타겟으로써 가능성' 의 참고문헌

  • β-Sheet augmentation is a conserved mechanism of priming HECT E3 ligases for ubiquitin ligation.
    430.18 : 3218-3233 [2018]
  • tribulations , and trends in tumor modeling in mice
    53-66 [2004]
  • the founding member of the BH3-only family proteins : mechanisms of cell death and role in cancer and pathogenic processes.
    27.1 : S20-S29 [2008]
  • p53-mediated suppression of BiP triggers Bik-induced apoptosis during prolonged endoplasmic reticulum stress.
    24.10 : 1717 [2017]
  • maintenance , and in vitro and in vivo applications of primary human glioblastoma multiforme xenograft models for translational biology studies and drug discovery
    52.1 : 14-16 [2011]
  • controls expression of the circadian transcription factor DBP.
    [2000]
  • al. , The brain tumor microenvironment.
    [2012]
  • al. , Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery.
    303:1323–9 [1980]
  • a novel ubiquitin-protein isopeptide ligase for dishevelled-1 , targets mutant superoxide dismutase-1.
    279.12 : 11327-11335 [2004]
  • a novel death-inducing protein shares a distinct sequence motif with Bcl-2 family proteins and interacts with viral and cellular survival promoting proteins. ,
    11 : 1921 – 1928 [1995]
  • Transcriptional activation of the proapoptotic bik gene by E2F proteins in cancer cells. ,
    580 ( 25 ) :5905-9 [2006]
  • Toward a more accurate quantitation of the activity of recombinant retroviruses : alternatives to titer and multiplicity of infection
    74.3 : 1258-1266 [2000]
  • The loss of circadian PAR bZip transcription factors results in epilepsy.
    1397-1412 [2004]
  • The expression of a new variant of the pro-apoptotic molecule Bax , Baxpsi , is correlated with an increased survival of glioblastoma multiforme patients.
    15 ; 11 ( 6 ) :675-87 [2002]
  • The endoplasmic reticulum-target protein Bik induces Hep3B cells apoptosis by the depletion of the ER Ca 2+ stores.
    33-38 [2008]
  • The Nedd4-like family of E3 ubiquitin ligases and cancer. ,
    26.3-4 : 587 [2007]
  • Targeted expression of BikDD combined with metronomic doxorubicin induces synergistic antitumor effect through Bax activation in hepatocellular carcinoma.
    6.27 : 23807 [2015]
  • TRAIL on trial : preclinical advances in cancer therapy.
    685-694 [2014]
  • Suppression of the death gene Bik is a critical factor for resistance to tamoxifen in MCF-7 breast cancer cells.
    43.6 : 1777-1786 [2013]
  • Structural analysis of the human pro-apoptotic gene Bik : chromosomal localization , genomic organization and localization of promoter sequences.
    254.1-2 : 157-162 [2000]
  • Snail depletes the tumorigenic potential of glioblastoma. ,
    32.47 : 5409 [2013]
  • Silver nanoparticle-induced hormesis of astrogliomaCells : A Mu-2-related death-inducing protein-orchestrated modus operandi. ,
    117:1147-1156 [2018]
  • Regulation of pattern recognition receptor signalling by phosphorylation and ubiquitination.
    45 : 162-170 [2018]
  • Radiochemotherapy in patients with primary glioblastomaComparing two temozolomide dose regimens.
    999-1005 [2008]
  • RNF43 interacts with NEDL1 and regulates p53-mediated transcription. ,
    404.1 : 143-147 [2001]
  • Proteasome inhibitors-mediated TRAIL resensitization and Bik accumulation.
    781-786 [2005]
  • Proteasome inhibition enhances the killing effect of BikDD gene therapy. ,
    7.2 : 319 [2015]
  • PAR bZIP-bik is a novel transcriptional pathway that mediates oxidative stress-induced apoptosis in fibroblasts.
    16 : 838 – 846 [2009]
  • Novel diagnostic and therapeutic approaches to malignant glioma.
    141 : w13210 [2011]
  • Molecular heterogeneity in glioblastoma : therapeutic opportunities and challenges.
    38 ( 2 ) :243–253 [2011]
  • Microarray analysis of epigenetic silencing of gene expression in the KAS-6/1 multiple myeloma cell line.
    64 , 3465–3473 [2004]
  • Methotrexate upregulates circadian transcriptional factors PAR bZIP to induce apoptosis on rheumatoid arthritis synovial fibroblasts.
    20.1 : 55 [2018]
  • Meta‐analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults.
    71 : 2585–97 [1993]
  • Malignant gliomas in adults.
    359:492- 507 [2008]
  • MUDENG is cleaved by caspase-3 during TRAIL-induced cell death.
    [2013]
  • Induction of cell death by the BH3- only Bcl-2 homolog Nbk/Bik is mediated by an entirely Bax-dependent mitochondrial pathway.
    22 : 3580 – 3590 [2003]
  • Induction of apoptosis by human Nbk/ Bik , a BH3-containing protein that interacts with E1B 19K. ,
    16 : 5857 – 5864 [1996]
  • Induction and endoplasmic reticulum location of Bik/Nbk in response to apoptotic signaling by E1A and p53.
    21 : 2534 – 2544 [2002]
  • Increased immune gene expression and immune cell infiltration in high-grade astrocytoma distinguish long-term from short-term survivors.
    1920–1927 [2012]
  • Guardians of cell death : the Bcl-2 family proteins.
    39 : 73-88 [2003]
  • Gliovis data portal for visualization and analysis of brain tumor expression datasets.
    139–141 [2017]
  • Glioblastoma update : molecular biology , diagnosis , treatment , response assessment , and translational clinical trials.
    1.563888889 [2017]
  • Glioblastoma multiforme : State of the art and future therapeutics.
    5:64–62 [2014]
  • Glioblastoma in elderly patients : A randomized phase III trial comparing survival in patients treated with 6-week radiotherapy versus hypofractionated RT over 2 weeks versus temozolomide single-agent chemotherapy.
    28.18suppl : LBA2002 [2010]
  • Genome engineering using the CRISPR-Cas9 system.
    8.11 : 2281 [2013]
  • Gene expression profiles of human glioblastomas are associated with both tumor cytogenetics and histopathology. ,
    991–1003 [2010]
  • Expression of the death gene Bik/Nbk promotes sensitivity to druginduced apoptosis in corticosteroid-resistant T-cell lymphoma and prevents tumor growth in severe combined immunodeficient mice.
    94 : 1100 – 1107 [1999]
  • Evolution of the cancer stem cell model.
    14:275–291 [2014]
  • Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study : 5year analysis of the EORTC-NCIC trial
    10:459–466 [2009]
  • Drug resistance in cancer : a perspective
    20 ( 1–2 ) :63–68 [2001]
  • Correlation of radiological and immunochemical parameters with clinical outcome in patients with recurrent glioblastoma treated with Bevacizumab.
    pp 1– 11 [2019]
  • Contributions of human tumor xenografts to anticancer drug development.
    7 [2006]
  • Characterization of MUDENG , a novel anti-apoptotic protein.
    [2016]
  • BH3-only protein Bik is involved in both apoptosis induction and sensitivity to oxidative stress in multiple myeloma.
    103.12 : 1808 [2010]
  • BH-3-only Bik functions at the endoplasmic reticulum to stimulate cytochrome c release from mitochondria.
    277.20 : 18053-18060 [2002]
  • Adenoviral natural born killer gene therapy for malignant glioma.
    14.13 : 1235-1246 [2003]
  • Activity-based E3 ligase profiling uncovers an E3 ligase with esterification activity. ,
    556.770 : 381 [2018]
  • Activation of multidomain and BH3-only pro-apoptotic Bcl- 2 family members in p53-defective cells. ,
    9 ( 6 ) :815-31 [2004]
  • A novel role for proline- and acid-rich basic region leucine zipper proteins in the transcriptional regulation of a BH3-only proapoptotic gene.
    281 : 38351-38357 [2006]
  • A novel protein MUDENG induces cell death in cytotoxic T cells.
    370 ( 3 ) :504-508 [2008]
  • A novel pathway of TEF regulation mediated by microRNA-125b contributes to the control of actin distribution and cell shape in fibroblasts.
    6.2 : e17169 [2011]
  • A light-inducible CRISPR-Cas9 system for control of endogenous gene activation.
    11.3 : 198 [2015]
  • A functional gene discovery in the Fas-mediated pathway to apoptosis by analysis of transiently expressed randomized hybridribozyme libraries.
    30 ( 16 ) :3609-3614 [2002]
  • 8. Molnar J. et al., Reversal of multidrug resistance by natural substances from plants., Curr Top Med Chem, 2010, 10(17): 1757–1768
  • 73. Chen R. et al., A hierarchy of self-renewing tumor-initiating cell types in glioblastoma., Cancer Cell, 2010, 17:362–375
  • 70. Stupp R. et al., Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma., N. Engl. J. Med., 2005, 352:987–996
  • 69. Fonjallaz P. et al., The two PAR leucine zipper proteins, TEF and DBP, display similar circadian and tissue-specific expression, but have different target promoter preferences., EMBO J, 1996, 351-362
  • 68. Falvey E. et al., DNA-binding specificity of PAR and C/EBP leucine zipper proteins: a single amino acid substitution in the C/EBP DNA-binding domain confers PAR-like specificity to C/EBP., Biol. Chem, 1996, 797-809
  • 65. Gomez-Bougie P. et al., Apoptotic machinery diversity in multiple myeloma molecular subtypes., Frontiers in immunology, 2013, 4: 467
  • 63. Pandya V. et al., The pro-apoptotic paradox: the BH3-only protein Bcl-2 interacting killer is prognostic for unfavorable outcomes in breast cancer., Oncotarget, 2016, 7.22: 33272
  • 60. Jiao S. et al., BikDDA, a mutant of Bik with longer half-life expression protein, can be a novel therapeutic gene for triple-negative breast cancer., PloS one, 2014, 9.3: e92172
  • 58. Kutuk O. et al., Biphasic ROS production, p53 and Bik dictate the mode of cell death in response to DNA damage in colon cancer cells., PloS one, 2017, 12.8: e0182809
  • 50. Goschl L. et al., FRI0055 Histone deacetylase 1 (HDAC1): a novel therapeutic target in rheumatoid arthritis., BMJ, 2017, 499-499
  • 49. Brosseau C. et al., Combination of lenalidomide with vitamin D3 induces apoptosis in mantle cell lymphoma via demethylation of Bik., cell death & disease, 2014, 5.8: e1389
  • 40. Li Y. et al., A novel HECT-type E3 ubiquitin protein ligase NEDL1 enhances the p53-mediated apoptotic cell death in its catalytic activity-independent manner., Oncogene, 2008, 27.26: 3700
  • 34. Sluimer J. et al., Regulating the human HECT E3 ligases, Cellular and molecular life sciences., 2018, 75.17: 3121-3141
  • 27. Letai A. et al., Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics., Cancer Cell, 2002, 2: 183 – 192
  • 26. Puthalakath H. et al., Keeping killers on a tight leash: transcriptional and post-translational control of the pro-apoptotic activity of BH3-only proteins., Cell Death Differ, 2002, 9: 505 – 512
  • 25. Hervouet E. et al., DNA methylation and apoptosis resistance in cancer cells., Cells, 2013, 2(3): 545–573
  • 21. Wagley Y. et al., A monoclonal antibody against human MUDENG protein., Monoclonal antibodies in immunodiagnosis and immunotherapy, 2013, 32.4: 277-282
  • 20. Agarwala SS. et al., Temozolomide: a novel alkylating agent with activity in the central nervous system, may improve the treatment of advanced metastatic melanoma., Oncologist, 2000, 5:144–51
  • 19. Wesolowski JR. et al., Temozolomide, American Journal of Neuroradiology., 2010, 31(8):1383-1384
  • 18. Mark R. et al., RTOG 0525: A randomized phase III trial comparing standard adjuvant temozolomide with a dose-dense schedule in newly diagnosed glioblastoma., Journal of Clinical Oncology, 2011, 29.15_suppl: 2006-2006
  • 11. Hirst J. et al., The fifth adaptor protein complex., PLoS Biol, 2001, p. e1001170
  • 10. Huang S., And now there are five: a new player in intracellular trafficking pathways., PLoS Biol, 2011, p. e1001173